TPST-2294

TPST-2294 is an orally bioavailable small molecule therapeutic being developed by Tempest Therapeutics for the treatment of renal cell carcinoma (RCC). Currently in Phase 1 clinical development as a monotherapy, the drug is part of a portfolio of small molecules designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. While the specific biological target of TPST-2294 is often kept undisclosed in company pipeline summaries, specialized biotech literature frequently identifies it as an antagonist of **HLA-G** (Human Leukocyte Antigen G), an immune checkpoint protein that contributes to tumor immune evasion by inhibiting T cells and Natural Killer (NK) cells. By blocking these inhibitory pathways, TPST-2294 aims to restore and enhance the body's natural immune response against renal malignancies.